Yonsei Med J.  2012 Nov;53(6):1113-1119. 10.3349/ymj.2012.53.6.1113.

Association of CYP2C19*2 and *3 Genetic Variants with Essential Hypertension in Koreans

• Shin DJ
• Kwon J
• Park AR
• Bae Y
• Shin ES
• Park S
• Jang Y

• KMID: 1414252
• DOI: http://doi.org/10.3349/ymj.2012.53.6.1113

Abstract

PURPOSE
The cytochrome P450 2C19 (CYP2C19) metabolizes arachidonic acid to produce epoxyicosanoid acids, which are involved in vascular tone and regulation of blood pressure. Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease. The aim of the present study was to evaluate the association between two variants, CYP2C19*2 (681G>A) and CYP2C19*3 (636G>A) and the development of essential hypertension (EH) in Koreans.
MATERIALS AND METHODS
We carried out an association study in a total of 1190 individuals (527 hypertensive subjects and 663 unrelated healthy controls). The CYP2C19 polymorphisms were genotyped using the SNaPShot(TM) assay.
RESULTS
The distribution of alleles and genotypes of CYP2C19*3 showed significant difference between hypertensive patients and normal controls (p=0.011 and p=0.013, respectively). Logistic regression analysis indicated that the CYP2C19*3 (636A) allele carriers were significantly associated with EH [odds ratio, 0.691; 95% confidence interval (CI), 0.512-0.932, p=0.016], in comparison to wild type homozygotes (CYP2C19*1/*1). Neither genotype nor allele distribution of CYP2C19*2 polymorphism showed significant differences between hypertensive and control groups (p>0.05).
CONCLUSION
Our present findings strengthen the evidence of an association between CYP2C19 gene polymorphism and EH prevalence. In particular, the CYP2C19*3 defective allele may contribute to reduced risk for the development of EH.

Keyword

Essential hypertension; CYP2C19; polymorphism; association study; Koreans

MeSH Terms

Adult
Alleles
Aryl Hydrocarbon Hydroxylases/*genetics
Asian Continental Ancestry Group/genetics
Female
Genotype
Homozygote
Humans
Hypertension/epidemiology/*genetics
Logistic Models
Male
Middle Aged
Polymorphism, Genetic/*genetics
Young Adult

Reference

1. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999. 66:185–192.

2. Bae Y, Park C, Han J, Hong YJ, Song HH, Shin ES, et al. Interaction between GNB3 C825T and ACE I/D polymorphisms in essential hypertension in Koreans. J Hum Hypertens. 2007. 21:159–166.

3. Turner ST, Boerwinkle E, Sing CF. Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension. 1999. 34(4 Pt 2):773–778.

4. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002. 3:561–597.

5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996. 6:1–42.

6. Rahman M, Wright JT Jr, Douglas JG. The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Am J Hypertens. 1997. 10:356–365.

7. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003. 35:99–106.

8. Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 2008. 9:691–702.

9. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001. 52:349–355.

10. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995. 28:328–332.

11. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002. 82:131–185.

12. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995. 58:404–411.

13. Brøsen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics. 1995. 5:312–317.

14. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994. 46:594–598.

15. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997. 7:59–64.

16. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004. 19:83–95.

17. Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther. 2006. 80:33–40.

18. Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol. 2001. 36:669–672.

19. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, Na-Bangchang K, Tawalee A, Krikreangsak N, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet. 2006. 21:286–290.

20. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther. 1998. 64:391–401.

21. Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit. 2007. 29:455–459.

22. Bertrand-Thiébault C, Berrahmoune H, Thompson A, Marie B, Droesch S, Siest G, et al. Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Ann Hum Genet. 2008. 72(Pt 2):178–183.

23. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics. 2011. 21:1–9.

24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. 18:499–502.

25. Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 2009. 9:380–394.

26. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000. 275:40504–40510.

27. Laffer CL, Laniado-Schwartzman M, Wang MH, Nasjletti A, Elijovich F. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension. Circulation. 2003. 107:574–578.

28. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension. 2003. 41(3 Pt 2):709–714.

29. Ercan B, Ayaz L, Ciçek D, Tamer L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct. 2008. 26:309–313.

30. Yang YN, Wang XL, Ma YT, Xie X, Fu ZY, Li XM, et al. Association of interaction between smoking and CYP 2C19^*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010. 16:579–583.

31. Ma Y, Ni W, Zhu W, Xiong Y, Deng X. Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population. Blood Press. 2011. 20:166–170.

32. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999. 9:539–549.

33. Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol. 2009. 104:46–51.